Compare Becton Dickinson and Co (BDX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs TotalEnergies SE — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while TotalEnergies SE trades at $80.86 (market cap $180.15B). The key difference: TotalEnergies SE is far larger — about 4.3× Becton Dickinson and Co's market cap, and TotalEnergies SE pays the higher dividend (5.21%). Which is the better fit depends on your goals.
| BDX | TTE | |
|---|---|---|
Market Cap | $41.51B | $180.15B |
Sector | Health | Energy |
52-Week High | $185.39 | $93.60 |
52-Week Low | $135.49 | $57.39 |
Enterprise Value | $57.97B | $214.29B |
Dividend Yield | 2.79% | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
TotalEnergies (TTE) trades at $81.21, up 3.45% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $2.45, beating expectations, but revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation ratios are attractive with a P/E of 12.05 and EV/EBITDA of 4.93. Recent news highlights strategic moves in LNG and solar divestments to focus on larger renewable projects.
The outlook for TTE is supported by strong cash flow generation and a 'Buy' consensus from 57.6% of analysts, but risks include declining revenue trends, geopolitical exposure, and regulatory pressures. The stock offers value with solid profitability and shareholder returns via dividends, yet investors should weigh execution risks in its energy transition strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
